Digest Network Come funziona
Network
/
Società
Re
Non verificato

Retension Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

3 comunicati stampa

Guarda tutti i comunicati
14/09/2026
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Retension Pharmaceuticals Announces Formation of Scientific Advisory Board
Fonte
Retension Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
10/09/2026
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Cardiologia
Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs
Fonte
Retension Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
21/08/2024
Scienza
Comunicazione
Medicina - Varie
Cardiologia
Sanità
Biotecnologia
Farmaceutica
Salute
Finanza
Industria
Retension Pharmaceuticals Closes $10.4 Million Oversubscribed Series A to Fund Clinical Trials for Patients Suffering from Resistant and Uncontrolled Hypertension
Fonte
Retension Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0